4.7 Review

Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

期刊

ANNALS OF ONCOLOGY
卷 24, 期 5, 页码 1189-1202

出版社

ELSEVIER
DOI: 10.1093/annonc/mdt001

关键词

diarrhea; enterocolitis; fever; gastrointestinal; neutropenia

类别

资金

  1. German Federal Ministry of Research and Education (BMBF) [01KN0706]
  2. Astellas Pharma
  3. Bayer
  4. Basilea
  5. Genzyme
  6. Gilead Sciences
  7. Pfizer
  8. Merck
  9. Optimer
  10. Schering-Plough
  11. Vicuron
  12. 3M
  13. Essex/Schering-Plough
  14. Gilead
  15. Janssen-Cilag
  16. Merck/MSD
  17. Novartis
  18. Roche
  19. Shire
  20. MSD

向作者/读者索取更多资源

Background: Cancer patients frequently suffer from gastrointestinal complications. However, a comprehensive, practical and evidence-based guideline on this issue is not yet available. Patients and methods: An expert group was put together by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO) to develop a guideline on gastrointestinal complications in cancer patients. For each subtopic, a literature search was carried out in PubMed, Medline and Cochrane databases and the strength of recommendation and the quality of the published evidence for major therapeutic strategies were categorized using a modification of the 'Infectious Diseases Society of America' criteria. Consensus discussions were held on each of the topics. Results: Recommendations were made with respect to non-infectious and infectious gastrointestinal complications. For all recommendations, the strength of the recommendation and the level of evidence are presented. Conclusion: This guideline is an evidence-based approach to the diagnosis and management of gastrointestinal complications in cancer patients.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据